Alkermes (NASDAQ:ALKS) EVP Sells 3,748 Shares

Alkermes plc (NASDAQ:ALKS) EVP Craig Hopkinson sold 3,748 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $30.00, for a total value of $112,440.00. Following the transaction, the executive vice president directly owned 65,740 shares of the company’s stock, valued at approximately $1,972,200. This trade represents a 5.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Alkermes Stock Up 0.8%

Shares of Alkermes stock traded up $0.22 during trading on Friday, reaching $29.52. The company’s stock had a trading volume of 1,810,097 shares, compared to its average volume of 1,942,554. The business has a 50 day moving average price of $30.42 and a 200-day moving average price of $29.38. Alkermes plc has a 12-month low of $25.17 and a 12-month high of $36.45. The company has a market capitalization of $4.87 billion, a P/E ratio of 14.61, a price-to-earnings-growth ratio of 1.42 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last issued its earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.41 by $0.08. Alkermes had a net margin of 22.27% and a return on equity of 21.81%. The company had revenue of $394.19 million for the quarter, compared to analyst estimates of $355.23 million. During the same period in the previous year, the firm earned $0.73 EPS. The business’s revenue was up 4.3% on a year-over-year basis. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. Research analysts predict that Alkermes plc will post 1.31 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on ALKS shares. Jefferies Financial Group set a $56.00 target price on shares of Alkermes and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Royal Bank Of Canada raised their price objective on Alkermes from $45.00 to $47.00 and gave the company an “outperform” rating in a research note on Wednesday, October 22nd. Needham & Company LLC boosted their target price on Alkermes from $43.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. JPMorgan Chase & Co. raised their price target on Alkermes from $34.00 to $35.00 and gave the company a “neutral” rating in a research report on Tuesday, September 9th. Finally, Mizuho lifted their target price on shares of Alkermes from $40.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $44.69.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Intech Investment Management LLC grew its stake in shares of Alkermes by 25.6% during the 1st quarter. Intech Investment Management LLC now owns 85,564 shares of the company’s stock valued at $2,825,000 after buying an additional 17,413 shares during the period. Baird Financial Group Inc. acquired a new position in Alkermes in the first quarter valued at $587,000. Acadian Asset Management LLC boosted its holdings in Alkermes by 2,422.0% in the first quarter. Acadian Asset Management LLC now owns 881,827 shares of the company’s stock valued at $29,100,000 after acquiring an additional 846,861 shares during the last quarter. Atle Fund Management AB grew its position in Alkermes by 5.8% during the second quarter. Atle Fund Management AB now owns 227,224 shares of the company’s stock valued at $6,501,000 after acquiring an additional 12,446 shares during the period. Finally, Capital Fund Management S.A. acquired a new stake in Alkermes during the second quarter worth about $1,142,000. Institutional investors and hedge funds own 95.21% of the company’s stock.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.